Social Worker and Psychotropic Medication Toward Effective Collaboration with Mental Health Clients, Families, and Providers

by Bentley, Kia J.; Walsh, Joseph

• ISBN13: 9780534340049
• ISBN10: 0534340040
• Edition: 1st
• Format: Paperback
• Copyright: 1995-11-20
• Publisher: Cengage Learning

Summary

Kia J. Bentley and Joseph Walsh present a book that is truly the first of its kind. All the facts, myths, and relevant information about psychotropic medication is presented to social workers in an easy-to-access manner.

Professionals and students alike will find this book to be a practical resource that helps them to be more responsive to the medication-related concerns of their mental health clients and to work more collaboratively on these issues with families and other mental health care providers. Rich in case examples and within a contemporary framework of "partnership" practice, this book provides an up-to-date primer on psychopharmacology and a review on psychosocial interventions to help in effective medication management.

Table of Contents

PART ONE SOCIAL WORK ROLES IN MEDICATION MANAGEMENT	1	(34)
CHAPTER 1 HISTORY AND OVERVIEW OF SOCIAL WORK ROLES IN MEDICATION MANAGEMENT	3	(17)
INTRODUCTION	3	(5)
Four Case Scenarios	3	(3)
The Changing Roles of Social Workers	6	(2)
A HISTORICAL CONTEXT OF INTERVENTION FOR PEOPLE WITH MENTAL ILLNESS	8	(4)
The Treatment Prior to 1950 of Persons with Mental Illness	8	(1)
The Rise of Psychiatric Social Work	9	(2)
The Introduction of Psychotropic Medication	11	(1)
SOCIAL WORK ROLE CATEGORIES	12	(6)
Physician's Assistant	12	(1)
Consultant/Collaborator	12	(1)
Monitor of Side Effects	13	(1)
Advocate	14	(2)
Educator	16	(1)
Researcher	17	(1)
SUMMARY	18	(2)
Social Work Roles Restated	18	(1)
Values	18	(2)
CHAPTER 2 DEFINING EFFECTIVE COLLABORATION	20	(15)
PRINCIPLES OF PARTNERSHIP MODEL OF PRACTICE	20	(6)
Appreciate Participants' Strengths and Limits	20	(1)
Appreciate Participants' Perspectives	21	(2)
View Relationship and Process Actively	23	(1)
Participate Equally in Problem Solving	24	(2)
MAINTAINING A BALANCED PERSPECTIVE	26	(4)
Rights of Individual, Family, and Society	26	(1)
Costs Versus Benefits of Medications	27	(1)
Expanded Roles with Regard for Related Professions	28	(2)
INTEGRATING PSYCHOSOCIAL INTERVENTIONS AND PSYCHOPHARMACOLOGY	30	(5)
Competing Ideologies	30	(1)
Managing Parallel Treatment	31	(4)
PART TWO A PRIMER ON PSYCHOPHARMACOLOGY	35	(86)
CHAPTER 3 BASIC PRINCIPLES: NEUROTRANSMISSION, PHARMACOKINETICS, AND PHARMACODYNAMICS	37	(22)
THE CENTRAL NERVOUS SYSTEM	38	(1)
THE BRAIN AND NERVOUS SYSTEM	38	(5)
PROPERTIES OF NERVE CELLS	43	(2)
NEUROTRANSMITTERS	45	(3)
Acetylcholine	46	(1)
Norepinephrine	47	(1)
Dopamine	47	(1)
Serotonin	47	(1)
Gamma Aminobutyric Acid (GABA)	48	(1)
HOW THE BODY HANDLES A DRUG	48	(3)
Absorption	48	(1)
Distribution	48	(1)
Metabolism	49	(1)
Excretion	50	(1)
THE EFFECTS OF A DRUG ON THE BODY	51	(1)
FOUR CLASSES OF PSYCHOTROPIC MEDICATION	52	(5)
Antipsychotic Medication	53	(1)
Antidepressant Medication	54	(1)
Mood-Stabilizing Drugs	55	(1)
Anti-Anxiety Medications	56	(1)
SUMMARY	57	(2)
CHAPTER 4 SPECIFIC MEDICATIONS FOR SPECIFIC DISORDERS	59	(46)
SIDE EFFECTS	59	(5)
Physical Side Effects: Definitions of Terms	60	(1)
Physical Side Effects: Factors in Their Production	61	(1)
Psychological Side Effects	62	(1)
Social Side Effects	63	(1)
ANTIPSYCHOTIC MEDICATIONS	64	(11)
Symptoms of Psychotic Disorders	64	(4)
Specific Medications	68	(4)
Case Examples	72	(3)
ANTIDEPRESSANT MEDICATIONS	75	(10)
Symptoms of Mood Disorders	76	(2)
Specific Medications	78	(3)
Case Examples	81	(4)
MOOD-STABILIZING MEDICATIONS	85	(10)
Symptoms of Mania	86	(1)
Specific Medications	87	(5)
Case Examples	92	(3)
ANTI-ANXIETY MEDICATIONS	95	(9)
Symptoms of Anxiety	95	(3)
Specific Medications	98	(4)
Case Examples	102	(2)
SUMMARY	104	(1)
CHAPTER 5 INTERVENTION CONCERNS WITH SPECIAL POPULATIONS	105	(16)
GENDER DIFFERENCES	105	(4)
General Considerations	105	(2)
Classes of Medication	107	(2)
OLDER ADULTS	109	(3)
General Considerations	109	(1)
Classes of Medication	110	(2)
CHILDREN AND ADOLESCENTS	112	(3)
General Considerations	112	(1)
Classes of Medication	113	(2)
RACIAL AND ETHNIC DIFFERENCES	115	(3)
PERSONS WITH A DUAL DIAGNOSIS OF MENTAL ILLNESS AND SUBSTANCE ABUSE	118	(1)
SUMMARY	118	(3)
PART THREE KNOWLEDGE AND SKILLS FOR PSYCHOSOCIAL INTERVENTIONS	121	(50)
CHAPTER 6 MEDICATION EDUCATION FOR CLIENTS AND FAMILIES	123	(13)
RATIONALE FOR MEDICATION EDUCATION	123	(4)
ISSUES IN IMPLEMENTING AND EVALUATING MEDICATION EDUCATION	127	(4)
CONTENT OF MEDICATION EDUCATION PROGRAMS	131	(4)
SUMMARY	135	(1)
CHAPTER 7 MEDICATION ADHERENCE AND REFUSAL	136	(16)
MODELS FOR UNDERSTANDING ADHERENCE	138	(7)
Characteristics of the Client	138	(2)
Aspects of Treatment	140	(3)
Aspects of the Social Environment	143	(1)
Aspects of the Illness or Symptoms	144	(1)
LEGAL AND ETHICAL ISSUES IN ADHERENCE AND REFUSAL	145	(3)
INTERVENTIONS TO ASSIST IN MEDICATION ADHERENCE	148	(4)
CHAPTER 8 MEDICATION MONITORING AND MANAGEMENT	152	(19)
CLIENT SELF-MONITORING OF MEDICATION	154	(2)
CONCRETE STEPS FOR COPING WITH SIDE EFFECTS	156	(2)
DECISION MAKING AND PROBLEM SOLVING IN MEDICATION MANAGEMENT	158	(5)
NEGOTIATING MEDICATION ISSUES WITH HEALTH CARE PROVIDERS	163	(3)
ADVOCACY IN MEDICATION MANAGEMENT	166	(5)
PART FOUR FUTURE DIRECTIONS	171	(12)
CHAPTER 9 FUTURE DIRECTIONS FOR PSYCHOPHARMACOLOGY: IMPLICATIONS FOR SOCIAL WORKERS	173	(10)
NEW TREATMENTS	173	(2)
EXPANDING PRESCRIPTION-WRITING PRIVILEGES	175	(2)
INCREASED PUBLIC SCRUTINY OF PSYCHOTROPIC MEDICATIONS	177	(1)
FINAL WORDS	177	(6)
REFERENCES	183	(16)
GLOSSARY	199	(18)
NAME INDEX	217	(3)
SUBJECT INDEX	220